Library > White Papers

A major new report led by the Novartis Foundation and Microsoft shows how investment in data and AI is critical to drive the health system improvements needed to respond to and recover from the COVID-19 pandemic and the world’s other greatest healthcare challenges.…

After several months of crisis, Medicines for Europe lays out some of the key lessons learned from COVID-19 for the future of pharmaceutical policy in Europe. The COVID-19 outbreak in Europe has catalysed some long-standing issues in the functioning of pharmaceutical policy,…

The Deloitte Intelligent biopharma series explores how artificial intelligence (AI) technologies will affect each step of the biopharma value chain. This report, the second in our series, examines how AI is helping to accelerate the efficiency and cost-effectiveness of drug…

The pace and scale of medical and scientific innovation is transforming the biopharma industry. The need for better patient engagement and experience is spurring new business models. Data generated, captured, analysed and used in real-time by innovative medical devices is…

Ten years on is the tenth annual report from the Deloitte Centre for Health Solutions exploring the performance of the biopharmaceutical industry and its ability to generate returns from investment in innovative new products.

This white paper was published by the Biosimilars Council, a division of the Association for Accessible Medicines. As prescription drug costs continue to increase, biosimilar medicines represent hope for patients seeking access to more affordable treatment.…

Serge Lapointe PhD, Partner and Patent Agent at Fasken Law Firm examines the current state of patents in the North American cannabis industry. Cannabis is licensed for medical purposes in Canada and, as of October 17, 2018, adult Canadians can legally consume cannabis for…